1 Min Read
Feb 8 (Reuters) - VIFOR PHARMA AG:
* FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL
* FIRST RESULTS FROM THE STUDY ARE EXPECTED IN THE SECOND HALF OF 2018 Source text - bit.ly/2FSyjCD Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.